Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging.

By A. Mariani, S. Dowdy, W. Cliby, B. Gostout, M. Jones, T. Wilson, K. Podratz. Gynecologic Oncology, 2008

813 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. (2015, background): “In the Mayo Clinic experience of 281 patients with endometrial cancer who underwent lymphadenectomy, 22% of patients with high-risk disease had lymph node metastases: 51% had both positive pelvic and para-aortic nodes, 33% had positive pelvic lymph nodes only, and 16% had isolated para-aortic lympha”
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer (2015, background): “In the MayoClinic experience of 281patientswith endometrial cancer who underwent lymphadenectomy, 22% of patients with highrisk disease had lymph nodemetastases: 51% had both positive pelvic and para-aortic nodes, 33% had positive pelvic lymph nodes only, and 16% had isolated para-aortic lymphadenop”
A clinically applicable molecular-based classification for endometrial cancers (2015, background): “…risk group stratification that is based on stage and the irreproducible variables of grade and histotype assignment (Fanning, 2001; Keys et al, 2004; Mariani et al, 2008; Kwon et al, 2009; Colombo et al, 2013; Kong et al, 2015), and is not highly predictive of outcomes (Bendifallah et al, 2015).”